Comment: PARP inhibitor olaparib plus bevacizumab in women with ovarian cancer
Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK
28 Sep 2019
More ovarian cancer patients benefit from maintenance combined targeted therapy
Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France
28 Sep 2019
Implementing national cancer control plans
Dr Eduardo Cazap and Dr Lisa Stevens
24 Jun 2019
The potential of PARP inhibitors in new cancer groups and in combination with ot...
Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston,...
18 Jun 2019
Cervical cancer screening in North Macedonia
Prof Shaban Memeti - Institute of Public Health, Skopje, North Macedonia
5 Jun 2019
Exercise: How it can help both during and after cancer treatment
Liz Davis - Cancer Exercise Specialist, London, UK
24 May 2019
Ovarian cancer: a current update
Prof Christina Fotopoulou - Queen Charlotte's and Chelsea Hospital, London, UK
24 May 2019
Ovarian cancer: Current treatments and latest advances
Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK
24 May 2019
The value of surgery in ovarian cancer
Prof Christina Fotopoulou - Queen Charlotte's and Chelsea Hospital, London, UK
24 May 2019
Latest in ovarian cancer treatment
Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK
24 May 2019
Bladder Problems following ovarian cancer treatment
Ellie Stewart - Guy’s and St Thomas NHS Foundation Trust, London, UK
24 May 2019
Treating ovarian cancer patients with PARP inhibitors
Kimberly Halla - Arizona Oncology Associates PC, Scottsdale, USA
8 May 2019
